•Innovent's Sycume meets phase 3 endpoint for inactive TED•Alcon's Brytly Redness Reliever Drops receive FDA approval•FDA approves RYZUMVI for presbyopia•Leadership watch: Saunders exits B+L, ZEISS names Vision Care CEO, and other executive moves•Roche reports phase 3 data on steroid-free therapy for UME management•Innovent's Sycume meets phase 3 endpoint for inactive TED•Alcon's Brytly Redness Reliever Drops receive FDA approval•FDA approves RYZUMVI for presbyopia•Leadership watch: Saunders exits B+L, ZEISS names Vision Care CEO, and other executive moves•Roche reports phase 3 data on steroid-free therapy for UME management
HEADLINES
FEATURED
LUCIA trial fails to meet primary goal; company to cut workforce reduction by 53% as part of a strategic prioritization to advance phase 3 DME program.
Earn FREE CE 24/7 with Courses by Eyes On Eyecare
Explore premium-quality, bite-sized courses featuring leading experts like Cecelia Koetting, OD, FAAO, and Cory Lappin, OD, MS, FAAO, and continuing education covering topics from ocular rosacea treatments to retinal disease.
